HLVX vs. KYTX, NVAX, EXAI, PRME, CRGX, RGNX, MESO, VALN, CABA, and ALEC
Should you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Kyverna Therapeutics (KYTX), Novavax (NVAX), Exscientia (EXAI), Prime Medicine (PRME), CARGO Therapeutics (CRGX), REGENXBIO (RGNX), Mesoblast (MESO), Valneva (VALN), Cabaletta Bio (CABA), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.
Kyverna Therapeutics (NASDAQ:KYTX) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.
18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of HilleVax shares are owned by institutional investors. 29.3% of HilleVax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
HilleVax's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.
HilleVax received 3 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users.
Kyverna Therapeutics presently has a consensus price target of $42.75, suggesting a potential upside of 192.81%. HilleVax has a consensus price target of $30.67, suggesting a potential upside of 119.20%. Given HilleVax's higher possible upside, equities research analysts plainly believe Kyverna Therapeutics is more favorable than HilleVax.
Kyverna Therapeutics has higher revenue and earnings than HilleVax.
In the previous week, HilleVax had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 5 mentions for HilleVax and 4 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.45 beat HilleVax's score of 0.05 indicating that HilleVax is being referred to more favorably in the news media.
Summary
Kyverna Therapeutics beats HilleVax on 6 of the 11 factors compared between the two stocks.
Get HilleVax News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HilleVax Competitors List
Related Companies and Tools
